Biogen Inc.
BIIB
Positions held
Your positionsBIIB isn't in your positions.
Add it to see shares, cost, and P&L here.
Bull / bear case
Site-generated summary from fundamentals, news, and score — not investment advice. As of 2026-10-07.
- Biogen's strong operating margins and consistent revenue growth position it well within the competitive landscape of the drug manufacturing industry.
- Revenue increased by 10% compared to the prior quarter, reaching $2.7 billion.
- The company maintains a gross margin of 71.6%, although slightly down from 73.3% in the previous quarter.
- Biogen faces challenges with a significant decline in earnings growth, which may impact investor confidence.
- The trailing P/E ratio stands at 39.73, indicating that the stock may be overvalued relative to its earnings.
- Net income for the most recent quarter was $97.5 million, a decrease from $319.5 million in the prior quarter.
Fundamentals
| Market cap | $32.27B | Enterprise value | $39.34B | Trailing P/E | 38.80 | Forward P/E | 13.22 |
| PEG | 2.29 | Price / book | 1.71 | Beta | 0.09 | Dividend yield | 0.00% |
| Revenue growth | 3.4% | Earnings growth | -84.8% | Gross margin | 78.3% | Operating margin | 25.1% |
| Profit margin | 8.3% | ROE | 4.6% | ROA | 5.2% | Debt / equity | 0.44 |
| Current ratio | 1.87 | Free cash flow | $1.27B | Analyst recommendation | buy | Mean target | $238.05 |
| 52w high | $230.49 | 52w low | $138.00 |
Quarterly
| 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | |
|---|---|---|---|---|---|
| Revenue | $2.7B | $2.5B | $2.3B | $2.5B | $2.6B |
| Op margin | 17.6% | 18.6% | 16.9% | 23.9% | 32.2% |
| Net income | $97.5M | $320M | -$48.9M | $467M | $635M |
| Gross margin | 71.6% | 73.3% | 78.3% | 73.4% | 77.1% |
| Gross profit | $2.0B | $1.8B | $1.8B | $1.9B | $2.0B |
| Operating income | $483M | $460M | $386M | $607M | $852M |
- Revenue +10% vs prior quarter ($2.7B vs $2.5B).
- Gross margin 71.6% (was 73.3% prior quarter).
Yearly (6y)
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $9.9B | $9.7B | $9.8B | $10.2B | — |
| Op margin | 25.0% | 23.6% | 18.8% | 28.5% | — |
| Net income | $1.3B | $1.6B | $1.2B | $3.0B | — |
| Gross margin | 75.7% | 76.1% | 74.2% | 77.6% | — |
| Gross profit | $7.5B | $7.4B | $7.3B | $7.9B | — |
| Operating income | $2.5B | $2.3B | $1.8B | $2.9B | — |
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-10-09 · Jefferies Adjusts Biogen Price Target to $260 From $255
2026-10-09 · UBS Adjusts Price Target on Biogen to $270 From $240, Maintains Buy Rating
2026-10-08 · RBC Cuts Price Target on Biogen to $256 From $260, Keeps Outperform Rating
2026-10-06 · Biogen expected to slightly beat third-quarter earnings as lupus trial data loom, Jefferies says
2026-10-06 · Will Biogen (BIIB) Beat Estimates Again in Its Next Earnings Report?
2026-10-02 · Can ABBV's New Parkinson's Pill Strengthen Its Neuroscience Franchise?
2026-10-01 · 1 Profitable Stock Worth Investigating and 2 We Ignore
2026-10-01 · HLS Therapeutics Announces Board of Directors Changes
2026-09-29 · Why Did KOD, RGEN, BIIB Stocks Rise To 52-Week Highs?
2026-09-28 · Can Biogen's Growth Portfolio Maintain Its Lead Over Legacy MS Drugs?
2026-09-25 · Biogen (NASDAQ:BIIB) Q2 Earnings: Leading The Therapeutics Pack
Price (daily)
Full chart · RSI · MACD · patterns